

Pharmacy and Therapeutics Committee Meeting Minutes

Thursday, March 15, 2018

7:15 a.m. to 8:45 a.m.

Cannon Health Building

Room 125

Committee Members Present:

Clinton Sheffield, MD
Abril Atherton, PharmD
Bryan Larson, PharmD
Clayton Grace, RPh

McKay Robinson, PharmD
Susan Siegfried, MD
Jake Jones, MD

Committee Members Excused:

Elizabeth Young, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Andrea Rico, CPhT

Robyn Seely, PharmD

Heather Santacruz, RN

Merelynn Berrett, RN

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez Alonso, B.Pharm, MSc MTSI, Medical Writer

Other Individuals Present:

Keri Smith, ViiV

Charissa Anne, J&J

Samantha Cicero, Neurocrine Biosciences

Maria Agapova, Teva

Kent Douglas, Neurocrine Biosciences

Cody Ball, SelectHealth

Dale Grant, Neurocrine Biosciences

Valerie Gonzales, U of U

Meeting conducted by: Clinton Sheffield

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting, and acknowledged a quorum.
2. **Review and Approval of February Minutes:** Clinton Sheffield made a motion to approve the minutes from February. Bryan Larson seconded the motion. All in favor, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Spinraza, established simple PA criteria.
4. **Extrapyramidal Disorder/Movement Disorder Agents (Benztropine, Deutetrabenazine, Tetrabenazine, Trihexyphenidyl, Valbenazine):** Elena Martinez presented a review of Extrapyramidal Disorder/Movement Disorder Agents. She presented peer-reviewed research regarding the safety and efficacy of each agent,

clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Public Comment:** Maria Agapova, Medical Outcomes Liaison for Teva pharmaceuticals, presented information pertaining to Austedo (deutetrabenazine). Samantha Cicero, Senior Medical Science Liaison for Neurocrine Biosciences, presented information pertaining to Ingrezza (valbenazine).
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.
7. **Committee Discussion:** Susan Siegfried shared some of her expertise and experience with the agents included in the review. Clinton Sheffield made a motion that the VMAT2 Inhibitors are similarly safe and efficacious for inclusion on the preferred drug list. Susan Siegfried seconded. Unanimous approval. Clinton Sheffield made a motion that the anticholinergic agents for movement disorders are similarly safe and efficacious for inclusion on the preferred drug list. Susan Siegfried seconded. Unanimous approval.
8. **Public Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Bryan Larson seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** April 19, 2018 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>